Toward Dissemination of Digital Therapeutics
CureApp and Teijin Pharma Sign Agreement for Joint Marketing and Salesof Prescription Digital Therapeutic App for Hypertension

Teijin Pharma Limited (Headquarters: Chiyoda-ku, Tokyo, President: Masaki Taneda, hereinafter Teijin
Pharma) and CureApp, Inc. ( Headquarters: Chuo-ku, Tokyo, President: Kohta Satake, hereinafter
CureApp) have concluded a joint marketing and sales agreement (hereinafter, joint agreement) for the"Prescription Digital Therapeutic App for Hypertension" (hereinafter, CureApp HT) as of April 1st. Throughthis partnership, we aim to expand the use of CureApp HT, which supports the lifestyle modifications thatare a prerequisite to any type of hypertension treatment. Further, through the distribution of digital
therapeutics (DTx)1, the two companies aspire to address unmet medical needs.

*1 Digital therapeutics: medical devices that have been approved by regulatory authorities fortheir therapeutic effects, intended for the treatment, management, and prevention of diseases.

About CureApp HT
In Japan, hypertension is recognized as a national disease and affects 43 million people, withrelated deaths reaching 100,000 annually. While both pharmacological and non-pharmacologicaltreatments for hypertension are available, lifestyle modification is important to the effectivenessin both of these options. Since individuals must make these lifestyle changes themselves,
adherence and habituation can be challenging.
CureApp HT is a medical device which has been proven to be as effective and safe as drugs in clinical
trials, and has obtained manufacturing and marketing approval in Japan. Physicians prescribe CureApp HT
at medical institutions, and patients download it on their smartphones. CureApp HT supports treatment
during intervals between medical consultations, promotes the acquisition of correct knowledge about
hypertension and changes in patient behavior and encourages the establishment of lifestylemodifications.
The Joint Agreement
The joint agreement is expected to further popularize CureApp HT by leveraging the product expertiseand knowledge of CureApp with the business portfolio of Teijin Pharma, which offers pharmaceuticals

and medical devices related to lifestyle-related diseases such as sleep apnea syndrome and diabetes. To
complement CureApp’s ongoing marketing and sales activities, Teijin Pharma will provide information
about CureApp HT to medical institutions throughout Japan, aiming to expand the number of prescribing
facilities and prescriptions.

Masaki Taneda, President of Teijin Pharma Limited
I am delighted to collaborate with CureApp, a leading DTx company, in promoting the adoption ofCureApp HT. This joint agreement allows us to fully leverage our unique business platform, which
provides a wide range of products and services, including pharmaceuticals, various medical devices, andpatient information sharing systems. By expanding the treatment options for hypertension, we aim tocontribute to the improvement of patients' quality of life.
Moreover, through synergies with our own lifestyle disease related products, treating diseases such as
sleep apnea syndrome and diabetes, we will continue to strengthen our business portfolio.
Kohta Satake, M.D. and Representative Di rector and CEO of CureApp, Inc.
CureApp is committed to solving societal issues in the medical field through the commercialization ofdigital therapeutics. We strive for a society where "all people can receive high-quality treatment withoutworry." Research and development of therapeutic apps has advanced domestically and internationally inrecent years. However, CureApp HT is the only digital medical device in Japan which has been clinically
proven to reduce blood pressure.
The 2024 medical fee revision will lead to a greater emphasis on the management of lifestyle-relateddiseases, such as hypertension, and we believe CureApp HT can assist doctors who are struggling toprovide lifestyle guidance.
In addition, consumer advertising of medical devices used by medical professionals is regulated in Japan.
However, to enable consumers to choose their appropriate treatment method, this prohibition was lifted
for CureApp HT in March 2024. In view of these circumstances, we are delighted to collaborate with Teijin
Pharma, which has a proven track record in promoting new treatments using medical devices in thedomestic market, on the social implementation of CureApp HT. By jointly promoting CureApp HT, which
supports the improvement of lifestyle habits that are the cause of hypertension, we expect to contributeto the health of more hypertension patients.

About the Teijin GroupTeijin (TSE: 3401) is a technology-driven global group with two core businesses: highperformance materials and healthcare solutions. Established in 1918 as Japan’s first rayon
manufacturer, Teijin today comprises some 170 companies employing 20,000 people in 20countries. Through “Human Chemistry, Human Solutions,” Teijin relentlessly strives to be acompany that supports the society of the future by protecting the global environment andaddressing the needs of people and communities. Teijin posted consolidated sales of JPY
1,032.8 billion (USD 6.6 billion) and total assets of JPY 1,251.0 billion (USD 8.0 billion) in thefiscal year ending March 31, 2024.

About CureApp, Inc.
Founded in 2014 by two physicians, CureApp, Inc. is a MedTech venture, a manufacturer of
medical devices that is involved in the research and development, production, and sale oftherapeutic apps which have demonstrated their effectiveness in a clinical trial, and areprescribed by doctors to patients at medical clinics.
In 2020, CureApp developed the world’s first smartphone-based medical device program fordisease treatment to receive regulatory approval and insurance coverage in the field ofsmoking cessation. The Company later was the first to receive regulatory approval in thefield of hypertension in April 2022, followed by insurance coverage in September of thesame year. CureApp is also proceeding with the development of a number of othertherapeutic apps for other diseases, including NASH, alcohol addiction, cancer, chronic
heart failure, and chronic low back pain. CureApp also operates the ascure mobile healthprogram for private companies, and the ascure Smoking Cessation program, which has
been implemented at 300 corporations (including 230 partnership agreements with healthinsurance associations). In addition, the Company launched the ascure Dr. Checkup
Reminder (Hypertension), a program to help patients with hypertension to schedule
checkups, on April 1, 2023, as well as introducing the ascure Aggravation Prevention (BloodPressure Course) on June 1.

Corporate Profile of CureApp, Inc.
Company Name: CureApp, Inc.
President and CEO: Kohta Satake, M.D.
Head Office Location: Kodenma-Cho YS Building 4th floor, 12-5, Nihonbashi KodenmaCho, Chuo-ku, Tokyo, Japan
Established: July 31, 2014
Business Description: Development of programmed medical devices, health-related
mobile services
URL: https://cureapp.co.jp/en/

Contact for this matter:
Teijin Limited Corporate Communications Department
Mail：pr@teijin.co.jp
CureApp, Inc. Public Relations
Mail：pr-team@cureapp.jp